Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · IEX Real-Time Price · USD
16.26
-0.24 (-1.45%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Y-mAbs Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019201820172016
Cash & Equivalents
78.64105.76181.56114.63207.14147.8790.5216.9
Cash & Cash Equivalents
78.64105.76181.56114.63207.14147.8790.5216.9
Cash Growth
-25.65%-41.75%58.39%-44.66%40.08%63.37%435.50%-
Receivables
22.4512.537.7100000
Inventory
5.076.75.5100000
Other Current Assets
4.965.457.477.734.823.660.840.36
Total Current Assets
111.11130.45202.26122.36211.96151.5391.3617.26
Property, Plant & Equipment
1.642.345.696.394.040.2100
Goodwill and Intangibles
2.632.991.6600000
Other Long-Term Assets
12.495.683.173.290.370.190.770
Total Long-Term Assets
16.7611.0110.529.684.410.390.770
Total Assets
127.87141.46212.78132.05216.37151.9292.1317.26
Accounts Payable
6.0614.1813.559.378.525.875.912.23
Current Debt
0.90.871.781.970.52000
Other Current Liabilities
13.1713.2412.548.24.553.252.020.75
Total Current Liabilities
20.1328.2827.8819.5413.599.127.932.98
Long-Term Debt
0.520.91.852.011.71000
Other Long-Term Liabilities
6.243.052.954.662.162.272.052.23
Total Long-Term Liabilities
6.763.954.86.683.882.272.052.23
Total Liabilities
26.8832.2432.6826.2117.4611.49.985.2
Total Debt
1.421.773.633.982.23000
Debt Growth
-19.69%-51.38%-8.67%78.43%----
Retained Earnings
-457.47-436.04-340.48-285.2-165.86-84.84-41.56-22.4
Comprehensive Income
0.451.331.37-0.530.050.01-0.170.03
Shareholders' Equity
100.99109.22180.11105.84198.9140.5382.1512.06
Net Cash / Debt
77.22104177.93110.66204.91147.8790.5216.9
Net Cash / Debt Growth
-25.75%-41.55%60.80%-46.00%38.57%63.37%435.50%-
Net Cash Per Share
1.772.384.122.765.825.144.671.20
Working Capital
90.98102.16174.39102.83198.37142.4183.4314.29
Book Value Per Share
2.312.504.172.645.654.884.240.86
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).